Introduction {#s1}
============

Proteins encoded by the TRPM3 gene form non-selective cation channels which are widely expressed in mammalian tissues. The discovery that TRPM3 can be activated by the endogenous neurosteroid pregnenolone sulphate (PS), has facilitated the study of this widely-expressed TRP channel and PS has been utilised as a pharmacological tool for channel characterisation and as a probe for TRPM3 expression ([@bib46]). TRPM3 is expressed in peripheral sensory neurons where it acts as a heat sensor ([@bib45]). Activation of TRPM3 channels in vivo has been shown to evoke nociceptive behaviours and mice without functional TRPM3 channels exhibit altered temperature preferences, compromised behavioural responses to noxious heat and fail to develop heat hyperalgesia associated with inflammation ([@bib45]).

There have been relatively few studies of the mechanisms which regulate or sensitise TRPM3. Many TRP channels are regulated by signalling pathways associated with activation of G-protein coupled receptors (GPCRs). For example, activation of both Gα~s~ and Gα~q~- coupled receptors can sensitise the heat sensitive nociceptor TRPV1 through protein kinase-dependent mechanisms ([@bib4]). Like other TRP channels, TRPM3 can be regulated by phosphoinositol 4,5-bisphosphate (PI(4,5)P~2~) and other phosphoinositides as loss or hydrolysis of PI(4,5)P~2~ leads to a reduction in TRPM3 activity that can be restored by application of exogenous PI(4,5)P~2~ ([@bib2]; [@bib40]). These findings suggest that TRPM3 activity can be regulated downstream of activation of G~q~ coupled GPCRs. A human TRPM3 variant with a short carboxyl terminus was found to be insensitive to stimulation of G~q~-coupled muscarinic receptors or histamine H1 receptors ([@bib20]). However, another human splice variant, TRPM3a, was shown to be activated by muscarinic receptor stimulation ([@bib26]), suggesting that individual genetic variants can be differentially regulated. Units of the G protein itself can directly interact with channel structures to modulate ion channel activity. Indeed activation of Gα~q~-linked receptors inhibits TRPM8 via a direct action of the Gα~q~ subunit with the TRPM8 channel ([@bib55]) and TRPM1 is inhibited by interactions with either Gα or Gβγ subunits ([@bib35]; [@bib50]).

In this study we have examined the effects of GPCR activation on the function of endogenously expressed TRPM3 channels in isolated DRG neurons from mice and investigated if activation of G~i/o~ coupled GPCRs can modulate TRPM3 mediated nociceptive responses in vivo. For these experiments we have studied three different receptors (opioid, GABA~B~ and neuropeptide Y) which are known to modulate sensory neuron activity ([@bib27]; [@bib34]; [@bib36]). We have also examined the underlying mechanism in CHO and HEK293 cells exogenously expressing TRPM3. Our results demonstrate that activation of these GPCRs inhibits TRPM3 activity in DRG neurons by a Gβγ mediated mechanism and inhibits PS-evoked nociceptive responses in mice.

Results {#s2}
=======

Morphine, Baclofen and PYY inhibit TRPM3 mediated PS-induced Ca^2+^ responses {#s2-1}
-----------------------------------------------------------------------------

Opioids remain one of the best known and most effective treatments for pain, and G~i/o~ coupled GPCRs for opioid ligands are expressed on sensory neurons where receptor activation inhibits voltage-gated calcium channels (VGCCs) ([@bib38]). Therefore, to determine if activation of G~i/o~ GPCRs can modulate natively expressed TRPM3 channels, we first examined the effects of the prototypical opioid receptor agonist, morphine.

We used two consecutive applications of a submaximal concentration of pregnenolone sulphate (PS, 20 µM,) to investigate the effect of morphine on TRPM3-mediated \[Ca^2+^\]~i~-responses in isolated DRG neurons. This concentration of PS typically activates about 30% of cells in DRG cultures. The first application of PS was used to identify TRPM3 expressing neurons and the second to assess the effects of pharmacological treatments. We refer to the response amplitude of the second PS challenge as R (relative % response). In control experiments, the second PS challenge evoked \[Ca^2+^\]~i~-responses (R) that were 63 ± 2% of the first PS response amplitude ([Figure 1a](#fig1){ref-type="fig"}). Treatment with morphine (10 µM) for 2 min before and during the second PS challenge significantly reduced R to 12 ± 1% (p\<0.001, [Figure 1b,c](#fig1){ref-type="fig"}). In the majority of PS-responsive neurons (55%, n = 115/209), application of morphine completely abolished PS-evoked \[Ca^2+^\]~i~ responses (R \< 5%).10.7554/eLife.26138.003Figure 1.Morphine inhibits TRPM3 channels expressed on sensory neurons.(**a**) Traces of DRG \[Ca^2+^\]~i~ responses evoked by two sequential PS challenges (20 µM) followed by high K^+^ (50 mM KCl). (**b**) Effect of treatment with 10 µM morphine for 2 min before and during the second PS challenge. F~(340/380)~ indicates fura-2 emission ratio. The lower panels in (**a**) and (**b**) are pseudocolour images illustrating the change in F340/380 ratio in response to PS and KCl. The bar indicates the colours corresponding to various F340/380 values. (**c**) Box and whisker plots and data points showing the amplitudes for responses to the second PS challenge in (**a**) and (**b**), \*\*\*p\<0.001; Mann-Whitney U test (control, n = 174; morphine, n = 209). (**d**) Effect of treatment with morphine (10 µM, n = 323), morphine (10 µM) and naloxone (1 µM, n = 110) and morphine (10 µM) following an incubation with pertussis toxin (200 ng/ml for 2.5 h-18h, n = 253) on \[Ca^2+^\]~i~ responses evoked by the second PS (20 µM) challenge using the protocol in (**a** and **b**). Control group, n = 188. (**e**) Traces displaying neuronal \[Ca^2+^\]~i~ responses to two PS (5 µM) challenges in the absence and presence of naloxone (1 µM), followed by a 50 µM PS challenge and high K^+^ (50 mM KCl). \*\*\*p\<0.001, compared to control. ††† p\<0.001, compared to morphine (10 µM), Kruskal-Wallis. (**f**) Whole cell recording illustrating that morphine reversibly inhibits PS-evoked outward membrane currents in DRG neurons (+40 mV). (**g**) Inhibitory effect of morphine on whole cell outward current in a CHO cell co-expressing TRPM3 and µ-opioid receptor (+60 mV). (**h**) Current-voltage relationships for another TRPM3/µ-opioid receptor expressing CHO cell measured at times corresponding to time points 1--5 in panel **g**.**DOI:** [http://dx.doi.org/10.7554/eLife.26138.003](10.7554/eLife.26138.003)

To confirm that the inhibitory effect of morphine is receptor mediated and not a direct effect of morphine on TRPM3, we examined the effect of morphine in the presence of the opioid receptor antagonist, naloxone. Naloxone (1 µM) inhibited the effect of morphine (10 µM) completely, since the relative amplitude (R) produced by the second PS challenge in the presence of morphine plus naloxone was 73 ± 3% (p\>0.05, [Figure 1d](#fig1){ref-type="fig"}), very similar to untreated control neurons (R = 64 ± 3%). Thus morphine inhibits TRPM3 by activating an opioid receptor present on DRG neurons.

The involvement of G~i/o~ proteins was investigated using pertussis toxin (PTX), which inhibits the coupling of G~i/o~ proteins to their cognate GPCRs by catalysing ADP-ribosylation of the Gα~i/o~ subunits. Incubation with PTX (200 ng/ml, for \~2 ½ −18 hr) significantly reduced the inhibitory effect of morphine in a large proportion of the neurons (morphine: R = 16 ± 2%; morphine +PTX: R = 46 ± 2%, p\<0.001, [Figure 1d](#fig1){ref-type="fig"}). These findings indicate that activation of a sensory-neuron expressed opioid receptor and subsequent Gα~i/o~ protein signalling is able to modulate the activity of TRPM3 channels. Opioid receptors, like many other types of GPCRs, may possess constitutive, agonist independent activity ([@bib31]). We tested whether such tonic receptor activity modulates the activity of endogenously expressed TRPM3 in DRG neurons, using two consecutive challenges of a low concentration of PS (5 µM) that evoked \[Ca^2+^\]~i~-responses in only a small percentage of neurons. In experiments where cells were exposed to naloxone during the second PS challenge the number of responding neurons increased significantly (p\<0.001, Fisher's) from 3.6% (n = 36/999) to 9% (90/999, [Figure 1e](#fig1){ref-type="fig"}). In contrast, the number of PS responders fell from 3.5% (n = 40/1153) to 1.8% (n = 21/1153) in control experiments. These findings indicate that constitutive activity of opioid receptors exerts a tonic inhibition of TRPM3 in DRG neurons.

We used patch-clamp recordings to confirm that the observed opioid receptor mediated inhibition of PS-evoked \[Ca^2+^\]~i~-responses is associated with a corresponding inhibition of TRPM3 currents in DRG neurons. TRPM3 currents have a marked outward rectification ([@bib46]) and we therefore studied neurons at a holding potential of +40 mV. Application of PS (50 µM) rapidly evoked membrane currents in a subset of isolated DRG neurons ([Figure 1f](#fig1){ref-type="fig"}). Subsequent introduction of morphine (10 µM) in the continued presence of PS produced a rapid, near-complete and reversible inhibition of the PS-evoked current. We next examined the effect of morphine on PS-evoked currents in CHO cells co-expressing TRPM3 and the µ opioid receptor. PS evoked large currents that were reversibly inhibited by co-application of morphine (inhibition 89 ± 4%, n = 9). Examination of the current-voltage relationships before and during PS application and in the presence of morphine ([Figure 1g](#fig1){ref-type="fig"}) showed that the response to PS was greatly inhibited by morphine at all voltages studied.

Morphine is a non-selective opioid receptor agonist and DRG neurons express all three naloxone-sensitive opioid receptor subtypes (µ, δ and κ). We examined the effects of sub-type selective opioid receptor agonists on PS-evoked \[Ca^2+^\]~i~ responses of DRG neurons, to determine which receptor subtype is important for morphine-induced inhibition of TRPM3. Treatment with the selective κ opioid receptor agonist U50488 (20 nM), did not inhibit PS-induced responses and instead produced a modest, but significant increase (U50488: R = 72 ± 3%; control: R = 57 ± 3%, p\<0.05, [Figure 2a](#fig2){ref-type="fig"}). The δ opioid receptor agonist SB205607 (20 nM) was without effect (SB205607: R = 52 ± 3%; p\>0.05, [Figure 2a](#fig2){ref-type="fig"}), whereas the μ opioid receptor agonist DAMGO (20 nM) significantly inhibited PS-evoked \[Ca^2+^\]~i~-responses to an extent similar to that previously observed with morphine (DAMGO: R = 18 ± 2%, p\<0.001, [Figure 2a,b](#fig2){ref-type="fig"}). These findings indicate that morphine predominantly inhibits TRPM3 by activating μ opioid receptors and suggest a high degree of co-expression of μ opioid receptors and TRPM3. These results are in keeping with earlier observations of μ (but not δ) opioid receptor expression in heat nociceptors ([@bib33]).10.7554/eLife.26138.004Figure 2.Activation of μ-opioid receptors inhibits TRPM3.(**a**) Effect of the selective μ opioid receptor agonist DAMGO, δ opioid receptor agonist SB205607 and κ opioid receptor agonist U50488 (each at 20 nM) on \[Ca^2+^\]~i~-responses evoked by PS (20 µM, second application, see [Figure 1](#fig1){ref-type="fig"} for protocol). \*p\<0.05, \*\*\*p\<0.001; Kruskal-Wallis (control, n = 152; DAMGO, n = 184; SB205607, n = 200; U50488, n = 140). (**b**) Traces displaying the effect of DAMGO (20 nM) on neuronal \[Ca^2+^\]~i~ responses to stimulation with PS (20 µM). F~(340/380)~ indicates fura-2 emission ratio. (**c**) Pseudocolour images illustrating the change in F340/380 ratio in response to PS and KCl with the colours corresponding to various F340/380 values indicated by the bar.**DOI:** [http://dx.doi.org/10.7554/eLife.26138.004](10.7554/eLife.26138.004)

We next examined whether GPCR inhibition of TRPM3 was specific to opioid receptors or could be extended to other G~i/o~-coupled receptors expressed on sensory neurons. The metabotropic G~i/o~-coupled receptors for GABA, GABA~B1~ and GABA~B2~, are expressed by a high percentage (60--90%) of peripheral sensory neurons ([@bib8]; [@bib10]; [@bib17]) and recently, activation of GABA~B1~ was shown to modulate activity of TRPV1 channels ([@bib21]). Treatment of DRG neurons with the selective GABA~B~ agonist baclofen (100 µM), significantly reduced the amplitude of the second PS response to R = 12 ± 2% compared to R = 58 ± 6% in control experiments (p\<0.001, [Figure 3a,b](#fig3){ref-type="fig"}) and abolished (R \< 5%) the PS-evoked \[Ca^2+^\]~i~ responses in 67% (n = 130/194) of neurons.10.7554/eLife.26138.005Figure 3.Activation of other Gi-coupled receptors also inhibit TRPM3.(**a, b**) Effect of (RS)-Baclofen (100 µM) on the relative \[Ca^2+^\]~i~-response amplitude evoked by PS (20 µM). (**c, d**) Effect of PYY (100 nM) on the relative \[Ca^2+^\]~i~-response amplitude evoked by PS (20 µM). Plots illustrate the response amplitudes evoked by the second PS challenge (% of first PS amplitude) in control experiments and experiments where neurons were perfused with (**b**) (RS)-Baclofen (control, n = 138; Baclofen, n = 194) and (**d**) PYY (control, n = 289; PYY, n = 217). \*\*\*p\<0.001; Mann-Whitney U test (**e**) Traces displaying \[Ca^2+^\]~i~ responses to two sequential 5 µM PS challenges, followed by a 50 µM PS challenge and depolarisation with high K^+^ (50 mM KCl). Cells were exposed to 10 µM BIIE 0246 for 2 min before and during the second PS challenge. (**f--h**) Traces displaying DRG \[Ca^2+^\]~i~ responses to sequential 20 µM PS challenges (indicated by black bars) in the presence and absence of morphine (10 µM), baclofen (100 µM) and PYY (100 nM), followed by depolarisation with high K^+^ (50 mM KCl). A group of cells were inhibited by some GPCR agonists but not others. F~(340/380)~ indicates fura-2 emission ratio. (**i**) Venn diagram illustrating the pattern of inhibition of PS responses by morphine, baclofen and PYY, n = 210 PS and KCl responsive cells. Responses in 31 cells were not inhibited by any of the GPCR agonists (second response amplitude \>15% of first PS response amplitude).**DOI:** [http://dx.doi.org/10.7554/eLife.26138.005](10.7554/eLife.26138.005)

The G~i/o~-coupled neuropeptide tyrosine (NPY) receptors Y1 and Y2, are each expressed on 15--20% of sensory neurons ([@bib53], [@bib54]; [@bib5]; [@bib24]; [@bib39]). The Y1 receptor is predominantly expressed in small diameter neurons whereas the Y2 receptor is largely expressed in medium and large diameter neurons. We examined whether activation of NPY receptors by the agonist peptide YY (PYY) was able to modulate neuronal TRPM3 \[Ca^2+^\]~i~-responses. Similarly to the effects of morphine and baclofen, application of 100 nM PYY reduced the PS-evoked \[Ca^2+^\]~i~ responses, and in 57% (n = 123/217) of neurons abolished the evoked increase in \[Ca^2+^\]~i~ (R \< 5%). The relative amplitude of the second PS-evoked \[Ca^2+^\]~i~ responses was reduced from 66 ± 3% in control experiments to 11 ± 1% in the presence of PYY (p\<0.001). Like opioid receptors, Y2 receptors have been reported to possess constitutive activity ([@bib9]) and we therefore examined whether tonic Y2 receptor activity modulates TRPM3. In experiments where we challenged neurons with two consecutive applications of a low concentration of PS (5 µM), treatment with the selective Y2 receptor antagonist BIIE 0246 (10µM) significantly (p\<0.05, Fisher's) increased the number of responding neurons from 1.1% (n = 5/450) to 4.2% (19/450; [Figure 3e](#fig3){ref-type="fig"}). In contrast, the number of PS responders fell from 3.4% (n = 15/440) to 1.8% (n = 8/440) in control experiments with two applications of 5 µM PS. These findings indicate that constitutive activity of Y2 receptors can exert a tonic inhibition of TRPM3.

To examine whether opioids, baclofen and PYY target distinct populations of TRPM3-expressing neurons, neurons were sequentially exposed to morphine (10 µM), baclofen (100 µM) and PYY (100 nM) and challenged with PS (20 µM) in the presence and absence of these drugs ([Figure 3f--h](#fig3){ref-type="fig"}). A large proportion of PS-sensitive neurons (43%, n = 91/210) were inhibited (response amplitude \<15% of first PS response amplitude) by all three agonists. A population of neurons was inhibited by morphine and baclofen but not PYY (7%, n = 14/210) and a slightly larger percentage of neurons was inhibited by morphine and PYY but not baclofen (13%, n = 27/210). Moreover, 10% (n = 21/210) of neurons were inhibited by baclofen and PYY but not morphine. Small populations of neurons were inhibited by just one agonist (morphine, 7%, n = 15/210; baclofen, 4%, n = 9/210; PYY, 4%, n = 9/210) and a subpopulation of neurons were not inhibited by any of the agonists (15%, n = 31/210). These findings, which are illustrated schematically in the Venn diagram ([Figure 3i](#fig3){ref-type="fig"}), indicate that morphine, baclofen and PYY target overlapping populations of TRPM3-expressing neurons.

Additional experiments demonstrated that not all G~i/o~-coupled receptors are able to effectively modulate TRPM3 activity. L-AP4 (5 µM) activation of group III metabotropic glutamate receptors (mGLUR~4/6/7/8~), which are expressed by DRG neurons ([@bib7]; [@bib19]), had no significant effect on PS-evoked \[Ca^2+^\]~I~ responses (R = 69 ± 3%, n = 100) compared to control (R = 61 ± 7%, n = 20; p\>0.05, Mann-Whitney U test). Cannabinoid CB1 receptors are expressed by a subset of DRG neurons ([@bib1]; [@bib42]). The CB1 receptor agonist WIN 55212--2 (1 µM) slightly but significantly reduced the amplitude of PS evoked \[Ca^2+^\]~i~ responses (R = 51 ± 3%; [Figure 4a](#fig4){ref-type="fig"}) compared to control (R = 62 ± 2%; p\<0.001, Mann-Whitney U test). This finding suggested that application of WIN 55212--2 inhibited PS-evoked responses in some but not in all DRG neurons. This was confirmed when DRG neurons were challenged with 3 applications of 20 µM PS with 1 µM WIN 552212--2 present before and during the second application and 1 µM WIN 55212--2 plus 0.5 µM AM251 (a CB1 receptor antagonist) present during the third PS application ([Figure 4b](#fig4){ref-type="fig"}). This experimental protocol allowed for detection of neurons whose PS evoked responses were inhibited by WIN 55212--2, and were restored when a CB1 antagonist (AM251) was co-applied with WIN 55212--2. In many DRG neurons, WIN 55212--2 had no obvious inhibitory effect ([Figure 4b](#fig4){ref-type="fig"}, top), but a small percentage of neurons (5%, n = 8/156) showed an AM251-reversible WIN 552212--2 inhibition of the PS response ([Figure 4b](#fig4){ref-type="fig"}, bottom). In view of the minor effect of CB1 receptor activation on DRG TRPM3 PS responses, we repeated the experiments in TRPM3 CHO cells transiently transfected with the CB1 receptor. As not all cells expressed CB1 after transfection, we compared the population responses to two consecutive PS applications. PS responses to the two PS applications were relatively stable in control cells not transfected with CB1, whereas WIN 552212--2 inhibited the PS responses in a sub-population of CB1 transfected cells. Furthermore, the second PS response of CB1 transfected cells was augmented by AM251 ([Figure 4c,d](#fig4){ref-type="fig"}). These results suggest that CB1 receptors can regulate TRPM3 but that there is either little co-expression of TRPM3 and CB1 in DRG neurons or ineffective coupling.10.7554/eLife.26138.006Figure 4.CB1 activation can inhibit TRPM3 channels.(**a**) Effect of CB1 receptor agonist WIN 55212--2 (1 µM) on DRG \[Ca^2+^\]~i~-responses evoked by PS (20 µM, second application). \*\*\*p\<0.001; Mann-Whitney U test (control, n = 213; WIN 55212--2, n = 218). (**b**) Traces showing DRG \[Ca^2+^\]~i~ responses to three PS (20 µM) challenges in the absence and presence of WIN 55212--2 (1 µM) and WIN 55212--2 (1 µM) plus AM251 (0.5 µM) followed by high K^+^ (50 mM KCl). Many PS responses were unaffected by WIN 55212--2 (upper panel) and some showed an inhibition that was reversed by co-application of the antagonist AM251 with WIN 55212--2 (bottom panel). (**c**) Traces displaying \[Ca^2+^\]~i~ responses to sequential 20 µM PS challenges (indicated by black bars) in CHO cells co-expressing TRPM3 and CB1 receptors in the absence (top) and presence (middle) of 1 µM WIN 552212--2 during the second PS challenge. Middle traces show cells where WIN 552212--2 inhibited the PS responses. Bottom: \[Ca^2+^\]~i~ responses to sequential applications of 5 µM PS with 0.5 µM present during the second PS application. (**d**) Plots showing the change in \[Ca^2+^\]~i~ response amplitudes (second -- first response). Note the increased number of negative values (inhibition) and the increased number of positive values (potentiation) in the presence of the agonist WIN 552212--2 and antagonist AM251, respectively.**DOI:** [http://dx.doi.org/10.7554/eLife.26138.006](10.7554/eLife.26138.006)

We next investigated whether morphine generally affected TRP channels in DRG neurons by examining its effect on TRPV1 responses to capsaicin. As capsaicin responses readily desensitize, we performed the experiments in the presence of cyclosporin (1 µM) which reduces TRPV1 desensitization ([@bib13]). DRG neurons were stimulated two or three times with 30 nM capsaicin with morphine present before and during the second capsaicin application ([Figure 5a](#fig5){ref-type="fig"}). Morphine had no significant inhibitory effect using this protocol ([Figure 5b](#fig5){ref-type="fig"}) in contrast to the marked inhibition of PS responses seen in the same experiments ([Figure 5c](#fig5){ref-type="fig"}).10.7554/eLife.26138.007Figure 5.Morphine does not inhibit capsaicin evoked \[Ca^2+^\]~i~-responses.Cyclosporin (1µM) included in all solutions to reduce TRPV1 desensitization. (**a**) Traces showing DRG \[Ca^2+^\]~i~ responses to three capsaicin (1 µM) challenges (indicated by black bars) followed by high K^+^ (50 mM KCl). Morphine (10 µM was present) before and during the second capsaicin challenge. Lower panels are pseudocolour images illustrating the change in F340/380 ratio in response to capsaicin and KCl. (**b**) Plots showing the change in \[Ca^2+^\]~i~ response amplitudes (second -- first response) under control conditions (left, Caps/Caps) and when morphine was applied (middle, Caps/Mor + Caps). (**c**) 10 µM morphine reduced \[Ca^2+^\]~i~ responses evoked by 20 µM PS in same experiment. Amplitudes of responses evoked by first PS application (left) and second application of PS in presence of morphine (right). \*\*\*p\<0.001**DOI:** [http://dx.doi.org/10.7554/eLife.26138.007](10.7554/eLife.26138.007)

Inhibition of TRPM3 is independent of cAMP and does not rely on Gα~i~ proteins {#s2-2}
------------------------------------------------------------------------------

Activation of Gα~i~ subunits leads to inhibition of adenylate cyclase, the enzyme responsible for producing cAMP (cyclic 3', 5'-adenosine monophosphate). Activation of protein kinase A (PKA) by cAMP and the resulting regulation of ion channel functions by PKA are well characterised. In order to examine whether opioid mediated inhibition of TRPM3 is driven by reduced levels of cAMP, we investigated whether morphine could still exert its inhibitory effects in the presence of a membrane permeable cAMP analogue, 8-bromo cAMP. 8-bromo cAMP was unable to compensate for the morphine-induced inhibition of PS responses. In experiments where 8-bromo cAMP (1 mM) was co-administered with morphine (10 µM) the response amplitude evoked by the second PS challenge was 11 ± 2% ([Figure 6a,b](#fig6){ref-type="fig"}) which was similar to the amplitude in the presence of morphine alone (13 ± 2%, p\>0.05, Kruskal-Wallis).10.7554/eLife.26138.008Figure 6.Opioid-mediated inhibition of TRPM3 is independent of cAMP and Gα~i~ subunits.(**a**) Traces showing the effect of 8-bromo cAMP (1 mM) on morphine (10 µM) induced inhibition of \[Ca^2+^\]~i~--responses evoked by PS (20 µM) in DRG neurons. F~(340/380)~ indicates fura-2 emission ratio. (**b**) Box and whisker and scatter plots displaying the average response amplitudes from experiments such as **a**., control, n = 96; morphine, n = 95; morphine +8 bromo cAMP, n = 118) \*\*\*p\<0.001, compared to control. (**c**) Whole cell recordings illustrating morphine inhibition of PS-evoked outward membrane currents in CHO cells co-expressing TRPM3 and the µ opioid receptor (+60 mV) in the absence (left) and presence (right) of 100 µM NF023 in the pipette solution. (**d**) Box and whisker and scatter plots showing the percentage inhibition of 50 µM PS-evoked currents in the absence and presence of NF023. No significant difference noted (p=0.1).**DOI:** [http://dx.doi.org/10.7554/eLife.26138.008](10.7554/eLife.26138.008)

In addition to initiating second messenger signalling pathways, Gα subunits can have direct actions on ion channels. To test the involvement of Gα~i~ subunits in opioid-mediated inhibition of TRPM3 we examined the effect of the selective Gα~i~-inhibitor NF023 ([@bib18]) on morphine-induced inhibition of PS responses. Although NF023 has been reported to inhibit Gαi-meditated signalling when applied extracellularly to cells ([@bib32]), this charged molecule probably has limited membrane permeability. We therefore examined electrophysiologically whether intracellularly applied NF023 would modify the effect of morphine on PS evoked currents in TRPM3/µ opioid receptor expressing CHO cells ([Figure 6c](#fig6){ref-type="fig"}). Inclusion of a high concentration (100 µM) of NF023 in the patch pipette had no marked effect on the inhibitory actions of morphine ([Figure 6d,e](#fig6){ref-type="fig"}). These findings indicate a Gα~i~- and cAMP-independent mechanism for opioid-induced inhibition of TRPM3.

Beta-gamma subunits of Gi proteins mediate inhibition of TRPM3 {#s2-3}
--------------------------------------------------------------

Activation of GPCRs also leads to the release of Gβγ subunits which are effector molecules themselves and can bind directly to ion channels to modulate their function ([@bib37]). We therefore examined the effect of morphine and baclofen on PS evoked responses in the presence of a Gβγ inhibitor, gallein. Morphine induced inhibition of PS evoked {Ca^2+^\]~i~-responses was dramatically supressed by gallein (20 µM, [Figure 7a,b](#fig7){ref-type="fig"}). The response amplitude evoked by the second PS challenge was 109 ± 5% in the presence of both morphine and gallein compared to just 10 ± 1% in the presence of morphine alone. In additional experiments with three PS challenges, a group of neurons were identified which showed reduced responses (\<30% of first response) to PS when morphine (10 µM) was present but regained sensitivity (\>50% of first response) when gallein (20 µM) was also present ([Figure 7c,d](#fig7){ref-type="fig"}).10.7554/eLife.26138.009Figure 7.βγ subunits mediate G~i/o~ inhibition of TRPM3.(**a, b**) Effect of the Gβγ inhibitor gallein (20 µM) on morphine (10 µM) induced inhibition of PS-evoked \[Ca^2+^\]i-responses. (**a**) Plots show the relative response amplitudes evoked by a second PS challenge (20 µM) in control conditions, in the presence of morphine and gallein, control n = 52; morphine n = 314; morphine + gallein n = 153. (**b**) Representative traces demonstrating that gallein reverses morphine inhibition of PS (20 µM). Cells were perfused with 10 µM morphine 2 min before and during the second and third PS challenge, and perfused with 20 µM gallein 7 min before and during the third PS challenge. The results shown are for morphine sensitive cells (PS response amplitude in presence of morphine \< 30% of the first response amplitude). \*\*\*p\<0.001 compared to control, †††p\<0.001 compared to morphine, Kruskal Wallis. (**c**) Scatter and line plot showing the relationship between maximum response amplitudes (Δ Fura-2 ratio) for the first, second and third PS responses in control experiments without gallein and (**d**) in experiments with gallein (20 µM) present during the third PS application. (**e,f**) Plots displaying the relative response amplitudes evoked by the second (20 µM) PS challenge for control experiments and experiments where neurons were perfused with (**e**) 100 µM baclofen or 10 µM gallein and 100 µM baclofen (control, n = 88 baclofen, n = 236; baclofen and gallein, n = 102). \*\*\*p\<0.001 compared to control, †††p\<0.001 compared to baclofen, Kruskal Wallis. (**f**) Effect of 100 nM PYY or 10 µM gallein and 100 nM PYY on the relative amplitude of PS evoked \[Ca^2+^\]~i~-responses (control, n = 65; PYY, n = 288; PYY and gallein, n = 183). \*\*\*p\<0.001 compared to control, ††p=0.01 compared to PYY. Kruskal-Wallis. F~(340/380)~ indicates fura-2 emission ratio.**DOI:** [http://dx.doi.org/10.7554/eLife.26138.009](10.7554/eLife.26138.009)

We next examined whether gallein also prevents baclofen-induced inhibition of PS-evoked \[Ca^2+^\]~i~-responses. When both gallein (10 µM) and baclofen (100 µM) were present during the second PS application, the maximum response amplitude was significantly higher than when baclofen was present alone (gallein and baclofen: 38 ± 4%, baclofen: 12 ± 2%, p\<0.001, ([Figure 7e,f](#fig7){ref-type="fig"}). Similarly, the inhibitory effect of PYY (100 nM) on PS-evoked \[Ca^2+^\]~i~-responses was attenuated in the presence of gallein (20 µM); the maximum response amplitude in the presence of both gallein and PYY was significantly higher than the maximum response amplitude in the presence of PYY alone (gallein and PYY: 36 ± 3%, PYY: 21 ± 2%, p\<0.001). Intriguingly, the scatter plots suggest that the inhibitory effect of gallein on baclofen and PYY mediated inhibition only occurred in a subset of neurons, unlike the strong effect noted for morphine inhibition in almost all cells. Nevertheless, these results indicate that TRPM3 activity can be regulated by a βγ-dependent mechanism after activation of opioid, GABA~B~ and NPY receptors.

To determine whether TRPM3 can be inhibited directly by Gβγ subunits in the absence of GPCR stimulation and Gα~i~ activation, we examined electrophysiologically the effect of intracellularly dialysing TRPM3 expressing HEK293 cells with Gβγ subunits (50 nM). Application of PS (50 µM) for 10 s every minute evoked large outward currents in TRPM3 HEK293 cells, without any detectable desensitization ([Figure 8a,b](#fig8){ref-type="fig"}). In contrast, intracellular dialysis with βγ-subunits (50 nM) produced a significant and progressive inhibition of the PS-evoked current amplitude ([Figure 8a,b](#fig8){ref-type="fig"}). To confirm the inhibitory effects of Gβγ subunits on TRPM3 we applied Gβγ subunits to the intracellular face of inside-out membrane patches from TRPM3 HEK293 cells stimulated with another, specific TRPM3 agonist, CIM0216. Macroscopic CIM-0216-evoked currents in these patches were greatly inhibited by 50 nM Gβγ subunits (Fig, 8 c, e) but not by administration of Gβγ subunits that had been heat denatured by boiling ([Figure 8d,e](#fig8){ref-type="fig"}). These results are consistent with direct inhibition of TRPM3 by Gβγ subunits.10.7554/eLife.26138.010Figure 8.Effect of βγ subunits on PS-evoked currents.(**a**) Outward currents (+40 mV) evoked by 10 s PS (50 µM) applications every minute in TRPM3-expressing HEK293 cells. Cells dialysed intracellularly with βγ subunits (50 nM, red trace) showed a progressive decline in the evoked current amplitude compared to control cells. (**b**) Column graph displaying normalised current (% of maximum current) for PS-evoked outward currents in TRPM3-expressing HEK293 cells. Columns represent mean ± SEM; \*\*p\<0.01, \*\*\*p\<0.001, unpaired t-test (control, n = 3--5 cells; βγ, n = 3--5 cells). (**c**) βγ subunits (50 nM) applied to the intracellular face of an inside out membrane patch from TRPM3-expressing HEK293 cell inhibit 10 µM CIM0216 evoked outward current (+60 mV). (**d**) Heat inactivated (100°C, 10 min) βγ subunits (50 nM) do not inhibit CIM0216 evoked currents. (**e**) Plots of percentage inhibition of CIM0216 evoked currents in inside out membrane patches for βγ subunits (n = 5) and boiled βγ subunits (n = 6).\*\* p=0.002**DOI:** [http://dx.doi.org/10.7554/eLife.26138.010](10.7554/eLife.26138.010)

G~i/o~ coupled GPCRs modulate TRPM3 mediated nociceptive responses {#s2-4}
------------------------------------------------------------------

We determined the effects of TRPM3 modulation in vivo by examining the nociceptive responses evoked by TRPM3 agonists in wild-type mice. Previous studies in TRPM3 knockout mice have shown that the behavioural responses to intraplantar injection of PS and CIM0216, are dependent on TRPM3 (35). The behavioural responses to either agonist alone were often mild. We therefore administered a combination of 5 nmole PS and 0.5 nmole CIM-0216 as these compounds have been shown to act synergistically in vitro ([@bib22]). Intraplantar administration of the combined agonists evoked robust paw licking/flinching behaviour that was measured over a 2 min period. Prior intraplantar administration of morphine (130nmole) essentially abolished the behavioural response evoked by PS/CIM0216 ([Figure 9a](#fig9){ref-type="fig"}), and intraplantar injections of either baclofen (240nmole) or PYY (235pmole) also significantly reduced the response ([Figure 9b](#fig9){ref-type="fig"}). Behavioural responses could be inhibited by morphine acting on, for example, voltage gated potassium channels in the periphery. We therefore examined the effects of intraplantar morphine on the paw licking/flinching responses evoked by intraplantar injection of capsaicin. Morphine had no inhibitory effect on capsaicin-elicited behaviours ([Figure 9e](#fig9){ref-type="fig"}) in marked contrast to its effect on PS/CIM0216 responses.10.7554/eLife.26138.011Figure 9.Nociceptive responses to TRPM3 agonists are modulated by Gi GPCR ligands.(**a,b**) Inhibitory effects of prior (5 min) intraplantar administrations of (**a**) 130 nmole morphine (n = 6 for each group) and (**b**) 240 nmole baclofen (n = 6) or 235 pmole PYY (n = 8) on the duration of licking/flinching evoked by intraplantar injection of 5 nmole PS plus 0.5 nmole CIM-0216 (n = 10 for PS + CIM0216). (**c,d**) Effects of prior (30 min) intraperitoneal administration of either (**c**) 2.5 mg/kg naloxone (n = 9 for PS, n = 8 for PS + naloxone) or (**d**) 3 mg/kg BIIE 0246 (n = 11 for PS, n = 8 for PS + BIIE 0246) on licking/flinching behaviour evoked by intraplantar administration of 5nmole PS. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001; ANOVA followed by Tukey's HSD test. (**e**) No effect of intraplantar morphine (130 nmole) on nociceptive responses evoked by intraplantar administration of capsaicin (33 nmole). Vehicle, 0.9% NaCl.**DOI:** [http://dx.doi.org/10.7554/eLife.26138.011](10.7554/eLife.26138.011)

Naloxone and BIIE0246 act as inverse agonists at μ opioid and NPY Y2 receptors ([@bib15]; [@bib47]) and consequently inhibit constitutive GPCR activity as well as inhibiting agonist evoked responses. As these ligands augmented TRPM3 activity in DRG neurons in vitro, we examined if they would increase the nociceptive effects of TRPM3 agonists. For these studies we used intraplantar injection of PS alone, which evoked relatively mild behavioural responses. Prior intraperitoneal administration of either 2.5 mg/kg naloxone ([Figure 9d](#fig9){ref-type="fig"}) or 3 mg/kg BIIE0246 ([Figure 9e](#fig9){ref-type="fig"}) resulted in significantly increased nociceptive responses to PS.

Discussion {#s3}
==========

TRPM3 is expressed in DRG neurons where it plays a role in the transduction of thermal (heat) stimuli in normal conditions and notably in the development of heat hypersensitivity in inflammatory conditions ([@bib45]). Studies of TRPM3 have been facilitated by the discovery of PS and the synthetic compound CIM0216 as TRPM3 agonists ([@bib46]; [@bib22]) that can be used to probe the functions and characteristics of TRPM3, and we have utilised these compounds to investigate the regulation of TRPM3 channels by GPCR ligands. Like other TRP channels, TRPM3 activity is regulated by intracellular PI(4,5)P~2~ and other phosphoinositides ([@bib2]; [@bib40]) but otherwise little is known about the mechanisms that regulate the activity of this channel. Other sensory neuron TRP channels, notably TRPV1 and TRPA1, are regulated downstream of GPCR signalling by mechanisms that involve either G~q~ activation, PI(4,5)P~2~ hydrolysis and protein kinase C or G~s~ activation leading to protein kinase A mediated phosphorylation. These and other phosphorylation pathways are important regulatory mechanisms for TRP channels particularly in inflammatory conditions (see [@bib41] for review). Activation of the G~i~ coupled µ opioid receptor is a potent analgesic mechanism in sensory systems and opioid agonists such as morphine can inhibit TRPV1 activity by reducing phosphorylation levels; however, this is evident only when TRPV1 is sensitized via the cAMP-PKA pathway ([@bib16]; [@bib43], [@bib44]). This latter observation is consistent with our observation that morphine has little or no inhibitory effect on capsaicin evoked Ca^2+^ responses when desensitization is blocked by cyclosporin.

Our results demonstrate for the first time that agonists acting at several G~i~ coupled GPCRs (µ opioid, GABA-B and NPY receptors) exert an inhibitory effect on TRPM3 activation in DRG neurons. This inhibitory effect was PTX-sensitive demonstrating a G~i/o~ protein involvement. The inhibition was not, however, mediated by the canonical Gα subunit/adenylate cyclase pathway as the inhibitory effect was not abrogated by either application of the Gα subunit inhibitor NF023 or by providing a membrane permeable cAMP analogue that is well known to activate PKA. Instead, our results indicate that the TRPM3 inhibition is mediated by Gβγ subunits. The Gα~i~ inhibitor NF023, which inhibits Gα~i~ subunit interactions with effector molecules, was without effect when dialysed into cells at 100 µM which is higher than its IC~50~ value (\~300--400 nM). However, Gα subunits bind to effector molecules with picomolar to nanomolar affinities and the effectiveness of NF023 will depend on its relative binding affinity for Gα~i~ compared to that of the effector molecules. We therefore cannot be certain that NF023 effectively inhibits Gα~i~ signalling even at the concentration used. In contrast, we have clear evidence for a role for Gβγ subunits.

The inhibitory effects of morphine on TRPM3 were reversed by gallein, which is generally considered to be a specific inhibitor of Gβγ signalling ([@bib29]), although we cannot exclude a non-Gβγ 'off target' effect. Critically, we found that PS evoked currents were inhibited by direct application of purified Gβγ subunits to either whole cells or excised inside-out membrane patches, without concomitant activation of Gα~i~ or G-protein-coupled receptors. The effect of the Gβγ subunits was lost after heat inactivation indicating that proteins in the sample were responsible for the inhibitory activity. Our findings are therefore consistent with activation of a µ opioid receptor and an action of Gβγ subunits to inhibit TRPM3. A direct interaction between the released Gβγ subunits and TRPM3 is likely as found for some other ion channels ([@bib15]; [@bib47]; [@bib41]). Gβγ subunits can, however, activate other molecules such as phospholipase C ([@bib30]), and such an action would hydrolyse PI(4,5)P~2~ and reduce TRPM3 activity ([@bib2]; [@bib40]). Inhibition of TRPM3 activity could therefore be due to a Gβγ/PLCmediated loss of PI(4,5)P~2~. PI(4,5)P~2~ levels are not maintained in isolated membrane patches and decline rapidly especially in the absence of Mg-ATP, which is required for phosphoinositide kinase mediated generation of PI(4,5)P~2~ ([@bib52]). This loss of PI(4,5)P~2~, accounts for the greatly reduced TRPM3 channel activity previously reported in excised membrane patches ([@bib2]; [@bib40]). In our excised inside-out patch experiments, recordings were made minutes after excision into Mg-ATP free solution, which will deplete PI(4,5)P~2~, and no further run down of channel activity was noted during the recordings. The finding that Gβγ subunits exerted a robust inhibitory effect on TRPM3 currents in membrane patches in these conditions suggests that the Gβγ inhibition does not involve PLC mediated hydrolysis of PI(4,5)P~2~. Such a conclusion is further supported by the observations in DRG Ca^2+^ imaging experiments where, in contrast to TRPM3, TRPV1 responses were not affected by morphine. As the activities of both channels are modulated by PI(4,5)P~2~ hydrolysis ([@bib2]; [@bib6]), the differential, strong inhibition of TRPM3 cannot be explained by PLC activation and a reduction in PI(4,5)P~2~.

Direct effects of G protein subunits on ion channel functions have been well studied for P/Q- and N-type voltage gated calcium channels ([@bib14]) and Kir channels ([@bib11]; [@bib51]). In contrast, there is relatively little knowledge of direct G protein subunit - TRP channel interactions. TRPM1 channels are inhibited by activation of G~o~--linked GPCRs and the available evidence is consistent with regulation by interactions direct between TRPM1 and both Gαο and Gβγ subunits ([@bib35]; [@bib50]; [@bib12]; [@bib25]). In other studies, TRPM8 was shown to be inhibited by an interaction with Gα~q~ ([@bib55]; [@bib28]) while TRPA1 activation following stimulation of MrgprA3 receptors in DRG neurons was inhibited by gallein and phosducin, consistent with a Gβγ mediated mechanism ([@bib49]). TRP channel regulation by direct G protein subunit interactions is therefore emerging as an important and novel mechanistic concept.

DRG neurons showed differential sensitivity to activation of different GPCRs. The TRPM3 responses in many neurons were inhibited by more than one GPCR agonist consistent with expression of multiple GPCRs in these neurons. Presumably the inhibition pattern reflects the distribution and expression levels of the different GPCRs. However, not all G~i/o~ GPCR agonists inhibited TRPM3. The group III mGluR agonist, L-AP4, and agonists at δ- and κ-opioid receptors did not significantly inhibit TRPM3 responses although there is good evidence for their expression in DRG neurons ([@bib33]; [@bib7]; [@bib19]; [@bib23]; [@bib48]). In part this could be explained by lack of TRPM3-GPCR co-expression in individual DRG neurons. For example, δ-opioid receptors are expressed by about 15% of, mainly larger diameter, DRG neurons ([@bib33]; [@bib3]) although there is evidence for some co-expression of μ- and δ-opioid receptors ([@bib12]), There is also likely to be an overlap in expression of G~i/o~ --coupled metabotropic glutamate GPCRs ([@bib7]; [@bib19]) with the small-medium diameter DRG neurons that express TRPM3 ([@bib45]). A significant inhibition of TRPM3 responses would therefore be expected in some DRG neurons, as seen for CB1 receptor activation ([@bib1]; [@bib42]). The effect of CB1 receptor activation in DRG neurons was restricted to a small number of neurons, although our experiments with heterologously expressed TRPM3 and CB1 indicated that CB1 receptor activity can regulate TRPM3. It is possible that specific macromolecular assemblies are required for the efficient interaction between types of GPCRs and TRPM3 and that δ- and κ-opioid and mGluR receptors do not contribute to these complexes, and that CB1 receptors are variably coupled in DRG neurons. The pronounced inhibition of TRPM3 by µ-opioid receptor activation is interesting as this receptor sub-type is expressed in mice in heat sensitive DRG neurons (see [@bib33]; [@bib23]) and may be functionally relevant for opioid control of heat sensation.

An interesting additional finding was that while both baclofen and PYY robustly inhibited TRPM3 responses in a substantial percentage of DRG neurons, this inhibitory effect was only partially reversed by gallein. In contrast, gallein strongly reversed the inhibitory effect of morphine on TRPM3. This finding raises the possibility that G~i/o~-coupled GPCRs can regulate TRPM3 via several signalling pathways.

In addition to demonstrating GPCR agonist induced inhibition of TRPM3, our in vitro studies have revealed that inverse agonists that act at µ-opioid and NPY receptors (naloxone and BIIE0246) can potentiate TRPM3 mediated responses. These findings are consistent with the concept that constitutive activity of µ-opioid and NPY receptors provides a level of tonic inhibition of TRPM3. A potentiating effect of these ligands was also noted in vivo, where they potentiated the behavioural effects of local intraplantar injection of PS. This result could reflect an inhibition of constitutive GPCR activity, as suggested by the in vitro findings, or inhibition of endogenous GPCR agonists produced in the tissues. Intraplantar administration of morphine, baclofen or PYY inhibited the strong nociceptive behavioural responses evoked by combined local application of PS and CIM0216. Such a peripheral anti-nociceptive action could be due to an action that inhibits action potential transmission, perhaps by activation of voltage gated potassium channels. However, morphine did not inhibit TRPV1-mediated, capsaicin-evoked pain responses so a general inhibitory action of morphine on the transmission of nociceptive signals can be ruled out. The inhibition of TRPM3-mediated nociceptive responses by the GPCR agonists can therefore be correlated to TRPM3 inhibition. Our results demonstrate that GPCR modulation of TRPM3 occurs in vivo and that the effects are localized to the regions of sensory nerve terminals rather than systemic effects operating at the level of the spinal cord or higher centres in the nociception pathway.

Our results demonstrate that TRPM3 in sensory neurons is subject to G~i/o~ GPCR regulation via a Gβγ subunit action. Activation of µ-opioid and GABA-B receptors are important analgesic mechanisms that operate both peripherally and centrally, including actions on the central terminals of sensory nerves in the spinal dorsal horn. Given the co-expression of TRPM3 and these GPCRs in nociceptive sensory neurons and the emerging role of TRPM3 in nociception, our findings highlight the importance of determining the role of TRPM3 in pathophysiological pain conditions.

Materials and methods {#s4}
=====================

Cell culture {#s4-1}
------------

DRG neurons were prepared from adult male or female C57Bl/6J mice using methods described previously^48^. Isolated neurons were plated on poly-d-lysine coated coverslips and maintained at 37°C in an atmosphere of 95% air-5% CO~2~ in MEM AQ (Sigma, Poole, UK) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml streptomycin, and 50 ng/ml NGF (Promega, Southampton, UK) for up to 24 hr before experimentation. HEK293 cells (RRID:[CVCL_U427](https://scicrunch.org/resolver/CVCL_U427), ThermoFisher Scientific) stably expressing TRPM3α2 plasmid (pcDNA3.1) DNA (provided by Dr Stephan Philipp; University of Saarland, Homburg, Germany) were grown in DMEM AQ supplemented with penicillin (100 U/ml), streptomycin (100 µg/ml), FBS (10%) and G418 (0.5 mg/ml). CHO cells (RRID:[CVCL_U424](https://scicrunch.org/resolver/CVCL_U424), ThermoFisher Scientific) stably expressing TRPM3α2 were grown in MEM AQ media with the same supplements noted for HEK293 cell growth. For some experiments, TRPM3 HEK293 or CHO cells were transiently transfected with plasmids encoding mouse µ opioid receptor-IRES-GFP (pCMV6, NM_001039652) or GFP tagged-rat CB1 receptor (pEGFP-N1, NM_012784.4), using Lipofectamine 2000 according to the supplier's protocol. All cells used were mycoplasma free.

Imaging changes in intracellular calcium levels {#s4-2}
-----------------------------------------------

DRG neurons were loaded with 2.5 µM Fura-2 AM (Molecular Probes) in the presence of 1 mM probenecid for \~1 hr. Dye loading and all experiments were performed in a physiological saline solution containing (in mM) 140 NaCl, 5 KCl, 10 glucose, 10 HEPES, 2 CaCl~2~, and 1 MgCl~2~, buffered to pH 7.4 (NaOH). Drug solutions were applied to cells by local microsuperfusion of solution through a fine tube placed very close to the cells being studied. The temperature of the superfused solution (24--25°C) was regulated by a temperature controller (Marlow Industries) attached to a Peltier device with the temperature measured at the orifice of the inflow tube. Images of a group of cells were captured every 2 s at 340 and 380 nm excitation wavelengths with emission measured at 520 nm with a microscope based imaging system (PTI, New Jersey, USA). Analyses of emission intensity ratios at 340 nm/380 nm excitation (R, in individual cells) were performed with the ImageMaster suite of software.

Electrophysiology {#s4-3}
-----------------

DRG neurons and TRPM3 expressing HEK293 or CHO cell lines were studied under voltage-clamp conditions using an Axopatch 200B amplifier and pClamp 10.0 software (RRID:[SCR_011323](https://scicrunch.org/resolver/SCR_011323), Molecular Devices). DRG neuron recordings were performed at +40 or+60 mV using borosilicate electrodes (3--6 MΩ) filled with (in mM): 140 CsCl, 10 EGTA, 1 CaCl~2~, 2MgATP, 2 Na~2~ATP, buffered to pH 7.4 (CsOH). DRG neurons were studied in the extracellular solution used for \[Ca^2+^\]~i~-measurements (see above). HEK293 and CHO cells were studied under Ca2+-free conditions (same solution as above, but with CaCl~2~ substituted by 1 mM EGTA). Excised inside-out membrane patch recordings were made using TRPM3 expressing HEK293 cells. The solution bathing the intracellular membrane face of excised membrane patches contained either (mM) 140 CsCl, 10 EGTA, 10 HEPES or 70 CsCl, 70NMDG-Cl, 10 EGTA, 10 HEPES pH7.3. For some experiments current-voltage relationships were obtained from voltage ramps (300 ms duration) from −100 mV to voltages up to +200 mV. The NMDG containing intracellular solution was used for voltage ramp studies to reduce the amplitude of the outward current.

βγ subunits from bovine brain (Millipore Ltd., Watford, UK) were dissolved in intracellular solution at a final concentration of 50 nM. For some experiment the βγ subunits were inactivated by heating to 100°C for 10 min. βγ subunits (plus CIM0216) were applied by pressure ejection from a blunt pipette positioned close to the excised membrane patch.

Behavioural assessment of pain responses {#s4-4}
----------------------------------------

All behavioural experiments were approved by the King's College London Animal Welfare and Ethical Review Board and conducted under the UK Home Office Project Licence PPL 70/7510. PS, or a combination of PS/CIM0216 (25 µl) and morphine, baclofen and PYY (10 µl) were injected subcutaneously into the plantar surface (intraplantar, i.pl.) of one of the hind paws using a 50 µl Luer-syringe (Hamilton Co.) fitted with a 26-gauge x 3/8 inch needle. Morphine, baclofen and PYY were injected 5 min before PS/CIM0216. Naloxone (2.5 mg/kg) and BIIE 0246 3 mg/kg were injected intraperitoneally 30 min prior to intraplantar injection of PS. Mice were habituated to the experimental Perspex chambers before the experiment and placed in the chambers immediately after injection of TRPM3 agonists. The duration of pain-related behaviours (licking and biting or flinching and shaking of the injected paw) was recorded using a digital stop-watch. Total pain response times over the first 2 min were used for analysis as the pain behaviours were largely restricted to this period. Groups of 6--11 animals were used for each agent. Pregnenolone sulphate (PS,): a 200 µM solution in PBS was prepared from a 60 mM DMSO stock solution. 25 µl was injected i.pl. into the left hind paw. CIM0216: a 20 µM solution was prepared from a 5 mM DMSO stock solution. A combined PS/CIM solution was prepared by combining 1 ml 400 µM PS with 1 ml 40 µM CIM and 25 µl was injected i.pl. into the left hind paw. Naloxone HCl was administered at a dose of 2.5 mg/kg i.p. 30 min prior to PS. Morphine, 100 µg in 10 µl was injected i.pl. 5 min prior to CIM/PREGS. Baclofen, 60 µg in 20 µl was injected i.pl. 5 min prior to CIM/PS. PYY, 1 µg in 10 µl was injected i.pl. 5 min prior to CIM/PS. BIIE 0246 was made up in saline from a 10 mM DMSO stock and dosed at 3 mg/kg i.p. 60 min prior to PS.

Materials {#s4-5}
---------

All compounds were from Sigma-Aldrich, Poole, UK unless otherwise stated. Stock solutions of pregnenolone sulphate, CIM0216 (Tocris Bioscience; Bristol, UK), WIN 55212--2 (Tocris Bioscience; Bristol, UK), AM251 (Tocris Bioscience; Bristol, UK), Gallein (Santa Cruz Biotechnology; Heidelberg, Germany) and BIIE 0246 (Tocris Bioscience; Bristol, UK) were made in DMSO (Calbiochem; Darmstadt, Germany). Stock solutions of morphine and naloxone were made in H~2~O and DAMGO (Tocris Bioscience; Bristol, UK), SB205607 (Tocris Bioscience; Bristol, UK), U50488 (Tocris Bioscience; Bristol, UK) and PYY (ABGent; San Diego, CA), were made in physiological extracellular solution. A stock solution of 8-bromo cAMP was made in H~2~O titrated with NaOH. Stock solutions of L-AP4 (Tocris Bioscience; Bristol, UK) and (RS)-Baclofen (Tocris Bioscience; Bristol, UK) were made in molar equivalent solutions of NaOH. Stock solutions were aliquoted and stored at −20°C. Stock solutions were diluted in physiological extracellular solution for their use in experiments. PTX (lyophilised powder) was reconstituted in H~2~O and was stored at 4°C. PTX was added to cells at a concentration of 200 ng/ml.

Statistical analysis {#s4-6}
--------------------

Data are presented as box and whisker plots showing the mean (square symbol), median (horizontal line), interquartile range (box) and 5% and 95% percentile points (whiskers). For the microfluorimetry and electrophysiology experiments, 'n' values represent the number of PS responding neurons or cells studied except where indicated otherwise in the text. For behavioural experiments, 'n' values represent the number of animals in each group. No statistical methods were used to predetermine sample sizes, however our sample sizes are similar to, or greater than, those generally employed in other studies in the field. Normality of data was tested using the Shapiro-Wilk Test. Differences in normally distributed data means between two groups were analysed using an independent samples t-test. Differences in normally distributed data means between three groups or more were analysed using a one-way ANOVA, followed by a Tukey's HSD post-hoc test. Differences in non-normally distributed data means between two groups were analysed using a Mann-Whitney U test. Differences in non-normally distributed data means between three groups or more were analysed using a Kruskal-Wallis test. All statistical analyses were made using IBM SPSS statistics, version 22 (RRID:[SCR_002865](https://scicrunch.org/resolver/SCR_002865)).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Gβγ mediate Gi/o coupled GPCR inhibition of TRPM3 in sensory neurons\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Kenton Swartz as the Reviewing Editor and Richard Aldrich as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Thomas Voets (Reviewer \#1); László Csanády (Reviewer \#2); and Alexander Chesler (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This manuscript is one of three that reports exciting new findings on the mechanism of inhibition of TRPM3 channel activity in dorsal root ganglion (DRG) sensory neurons by stimulation of G protein-coupled receptors (GPCRs). Although all three manuscripts received favorable reviews, the essential revisions will require different amounts of time to address, and we encourage the authors to coordinate submission of their revised manuscripts.

The general conclusion of this manuscript is that TRPM3 channel currents are directly inhibited by G-β-γ subunits released upon stimulation of various GPCRs coupled to heterotrimeric Gi/o proteins, and this inhibition is independent of any effects on cAMP concentrations. The majority of experiments reflect Ca^2+^ imaging on dissociated dorsal root ganglion (DRG) neurons, except for a few whole-cell patch-clamp recordings, and some behavioral experiments in live animals. This study was less mechanistically oriented than the companion submissions by two other groups, and some conclusions rely on faith in generally accepted phenomena. These include the potential effects on PIP2 levels that are not directly addressed (the assumption is that those remain unaffected by the Gi/o pathway), and the involvement of G-α is excluded simply based on the lack of effect of a known G-α inhibitor. On the other hand, the results of this study complement those of the co-submissions in several ways:

i\) TRPM3 inhibition through a different subset of GPCRs present in DRG neurons is investigated here. Stimulation of opioid μ,GABA-B, neuropeptide Y, and cannabinoid CB1 receptors are shown to inhibit TRPM3 currents in subpopulations of DRG neurons.

ii\) Stimulation of submaximally activated TRPM3 channels by inverse agonists of either opioid μ or NPY receptors suggests some tonic inhibition of TRPM3 currents by constitutive activity of these GPCRs (or perhaps the presence of low levels of endogenous ligands). The relevance of this tonic inhibition is also demonstrated through in vivo experiments that show increased sensitivity to TRPM3 agonist-induced pain in the presence of opioid μ or NPY receptor blockers.

Essential revisions:

1\) What is missing in this manuscript is an indication of the selectivity of the receptor activation towards TRPM3-dependent pain signals. To correlate the reduced pain response in the presence of morphine or baclofen to the inhibition of TRPM3 function, it is essential to show that other TRPM3-independent pain responses are not affected. This would involve demonstration that neuronal calcium signals and pain evoked by e.g. capsaicin or mechanical stimuli are not affected by these agonists.

2\) This study would be greatly strengthened if the authors showed that activation of one of their GPCRs could inhibit TRPM3 currents in HEK cells. It would also be good to demonstrate that G-β/γ applied to inside out patches can inhibit TRPM3 to strengthen the claim of a direct interaction with the channel. It is also not clear what the control condition is for [Figure 5G-H](#fig5){ref-type="fig"}, but ideally it would be boiled GBG protein.

3\) To fully evaluate the quality and robustness of calcium imaging data it is helpful to have representative images as well as traces. This would allow the reader to appreciate the density and health of the cells and neurons as well as the robustness of the responses. Also, glia vs. neurons in the culture should not be highlighted. Absence of KCl response is a poor proxy for glial identification -- if this is the only criteria, then calling those cells KCl-negative cells is more appropriate.

4\) The scatter of data used to generate bar graphs is unclear. These should be included on all summary plots throughout the manuscript to provide a better sense of the effect size and variability. The number of tested cells is quite low for the experiments in [Figure 3F-H](#fig3){ref-type="fig"}, so it is unclear how significant and representative the derived percentages are. The authors should also provide information on how many neurons responded to PS and what percentage of them are inhibited by Gi/o agonists?

5\) There are no positive controls in [Figure 4](#fig4){ref-type="fig"}. Since these are all negative findings, it is difficult for the reader to appreciate how well the pharmacological manipulations are working.

6\) Gallein is known to inhibit other targets, the short comings of this drug should at least be discussed, and it would be ideal if orthogonal approaches to interfere with GBG signaling were added to strengthen the findings (such as PTX or BARK-ct).
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Author response

*Essential revisions:*

*1) What is missing in this manuscript is an indication of the selectivity of the receptor activation towards TRPM3-dependent pain signals. To correlate the reduced pain response in the presence of morphine or baclofen to the inhibition of TRPM3 function, it is essential to show that other TRPM3-independent pain responses are not affected. This would involve demonstration that neuronal calcium signals and pain evoked by e.g. capsaicin or mechanical stimuli are not affected by these agonists.*

We have added experiments examining the effects of morphine on capsaicin-evoked Ca^2+^ responses in DRG neurons and capsaicin-evoked pain responses in vivo. For the former experiments we used conditions where TRPV1 desensitization was greatly reduced by the presence of cyclosporin to inhibit calcineurin. Under these conditions, morphine did not inhibit TRPV1 (new [Figure 5](#fig5){ref-type="fig"}). In vivo, morphine did not affect the nocifensive, behavioural responses (licking/flinching) evoked by local intraplantar injection of capsaicin (new [Figure 9E](#fig9){ref-type="fig"}). The inhibitory effect of morphine on licking/flinching evoked by the TRPM3 agonists therefore correlates with inhibition of TRPM3 activity rather than a general inhibition of sensory neuron responses.

*2) This study would be greatly strengthened if the authors showed that activation of one of their GPCRs could inhibit TRPM3 currents in HEK cells. It would also be good to demonstrate that G-β/γ applied to inside out patches can inhibit TRPM3 to strengthen the claim of a direct interaction with the channel. It is also not clear what the control condition is for [Figure 5G-H](#fig5){ref-type="fig"}, but ideally it would be boiled GBG protein.*

We have added the results of experiments where we applied G-β/γ subunits directly to inside-out membrane patches from TRPM3 expressing HEK293 cells. These results complement the whole cell experiments in the original submission. G-β/γ subunits inhibited CIM0216 currents in the excised membrane patches by \~50% similar to the inhibition noted in whole cell experiments. As a control we used heat inactivated (boiled) G-β/γ subunits as suggested. The latter had no inhibitory effect on the CIM0216 evoked currents in inside-out membrane patches.

*3) To fully evaluate the quality and robustness of calcium imaging data it is helpful to have representative images as well as traces. This would allow the reader to appreciate the density and health of the cells and neurons as well as the robustness of the responses. Also, glia vs. neurons in the culture should not be highlighted. Absence of KCl response is a poor proxy for glial identification -- if this is the only criteria, then calling those cells KCl^-^negative cells is more appropriate.*

We have added representative images of the cells and Fura-2 fluorescence signals in [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"} to provide the requested information on the density of cells in the preparation. The term glia was not used in the original manuscript and we made no comment about non-neuronal cells. We do not believe that there are any non-neuronal cells in our preparation that will respond to a high K^+^ solution with a robust increase in intracellular calcium concentration. However, we have replaced the term 'neuron' with 'cells' in many places as a positive response to the reviewers' comment.

*4) The scatter of data used to generate bar graphs is unclear. These should be included on all summary plots throughout the manuscript to provide a better sense of the effect size and variability. The number of tested cells is quite low for the experiments in [Figure 3F-H](#fig3){ref-type="fig"}, so it is unclear how significant and representative the derived percentages are. The authors should also provide information on how many neurons responded to PS and what percentage of them are inhibited by Gi/o agonists?*

We have replaced the bar graphs with box and whisker plots and show all data points for all experiments. Data from additional experiments have now been added to the original [Figure 3F-H](#fig3){ref-type="fig"} data set increasing the number of PS-/KCl-responsive cells to 210. We believe that this gives a more accurate account of the percentages of cells affected by the various agonists. The results are also now summarized in Venn diagram ([Figure 3I](#fig3){ref-type="fig"}).

*5) There are no positive controls in [Figure 4](#fig4){ref-type="fig"}. Since these are all negative findings, it is difficult for the reader to appreciate how well the pharmacological manipulations are working.*

The ability of 8-bromo-cAMP to stimulate PKA has been well established in numerous published experiments and one of the authors has published showing that it affects histamine evoked DRG Ca^2+^ responses at the concentration used in the current experiment (Nicolson TA, Foster AF, Bevan S, Richards CD. 2007 Prostaglandin E2 sensitizes primary sensory neurons to histamine. Neuroscience. 150:22-30). We have not therefore added experimental data on the ability of this compound to stimulate cAMP pathways.

We acknowledge that the action of NF023 in experiments in the original submission was questionable as the compound was applied to intact cells in calcium imaging experiments. Although the compound has been reported to affect intact cells, we believe that it will not cross the plasma membrane easily. We have therefore now included experiments where it is included in the pipette solution at a high concentration (100µM) in whole cell recordings experiments on TRPM3-expressing CHO cells (new [Figure 6](#fig6){ref-type="fig"}). This concentration of NF023 is higher than its reported IC50 value (300-400nM). The compound had no effect on morphine inhibition. In the absence of a direct positive control for the activity of the compound we have added a caveat about interpretation of the negative result and state in the Discussion 'We therefore cannot be certain that NF023 effectively inhibits Gαi signalling even at the concentration used.'

6\) Gallein is known to inhibit other targets, the short comings of this drug should at least be discussed, and it would be ideal if orthogonal approaches to interfere with GBG signaling were added to strengthen the findings (such as PTX or BARK-ct).

Experiments showing that PTX inhibits the effect of morphine were included in the study. We have made the wording slightly more prominent to emphasize this.

We have also added a caveat that gallein could have 'off target' non-G-β/γ subunit effects. This comment could probably be applied to almost any inhibitor used. We could not find published data that gallein inhibited other targets other than those where the effects were interpreted as being via a G-β/γ pathway. We would appreciate any information from the reviewers on this point.
